We performed an in vitro evaluation of the effect of maraviroc or dolutegravir on bilirubin to albumin binding. At typical treatment and low albumin concentrations, maraviroc had no impact, while dolutegravir affected bilirubin to albumin binding to an equivalent extent as sulfisoxazole. However in vivo, neither is likely to significantly impact bilirubin to albumin binding because of their low concentrations relative to albumin.
No takes yet. Share an insight, caveat, or question.
Schreiner et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: